tafenoquineの例文

• Like primaquine, tafenoquine causes hemolysis in people who are G6PD deficient.
• Tafenoquine is currently in Phase III clinical trials and is not yet available to prescribe.
• Like primaquine, tafenoquine causes hemolysis in people with G-6-P deficiency.
• In 2013 a Phase IIb trial was completed that he studied a single-dose alternative drug named tafenoquine.
• The 8-aminoquinoline family of drugs contains three members, primaquine, tafenoquine and pamaquine and are used in the treatment of malaria.
• "' Tafenoquine "'is an 8-aminoquinoline drug manufactured by GlaxoSmithKline that is being investigated as a potential treatment for malaria, as well as for malaria prevention.
• Indeed, the long half-life of tafenoquine suggests that particular care should be taken to ensure that individuals with severe G-6-P deficiency do not receive the drug.
• The dose of tafenoquine has not been firmly established, but for the treatment of " Plasmodium vivax " malaria, a dose of 800 mg over three days has been used.
• The proposed indication for tafenoquine is for treatment of the hypnozoite stages of " Plasmodium vivax " and " Plasmodium ovale " that are responsible for relapse of these malaria species even when the blood stages are successfully cleared.
• This is only now achieved by administration of daily primaquine for 14 days . The main advantage of tafenoquine is that it has a long half-life ( 2 3 weeks ) and therefore a single treatment may be sufficient to clear hypnozoites.